Two Sigma Advisers
LENZ

Two Sigma Advisers’s LENZ Therapeutics LENZ Stock Holding History

Two Sigma Advisers’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,426
Closed -$1.24M – 2238
2025
Q4 		$1.24M Buy
77,426
+69,729
+906% +$2.03M ﹤0.01% 1385
2025
Q3 		$359K Buy
+7,697
New +$283K ﹤0.01% 1904
2024
Q1 		– Sell
-19,329
Closed -$354K – 2663
2023
Q4 		$354K Sell
19,329
-3,857
-17% -$63.7K ﹤0.01% 2049
2023
Q3 		$403K Buy
23,186
+443
+2% +$7.7K ﹤0.01% 1868
2023
Q2 		$414K Sell
22,743
-7,086
-24% -$142K ﹤0.01% 1875
2023
Q1 		$512K Sell
29,829
-6,628
-18% -$107K ﹤0.01% 1940
2022
Q4 		$847K Sell
36,457
-1,600
-4% -$37.1K ﹤0.01% 1645
2022
Q3 		$844K Buy
38,057
+3,814
+11% +$90.9K ﹤0.01% 1607
2022
Q2 		$659K Buy
+34,243
New +$763K ﹤0.01% 1797

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Two Sigma Advisers's LENZ Position: Q1 2026 in Review

Two Sigma Advisers sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 77,426 shares — an estimated $1.24M sold.

Two Sigma Advisers first reported a position in LENZ in Q2 2022 and held it in 9 quarters. The position peaked at $1.24M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Two Sigma Advisers reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 77,426 LENZ Therapeutics shares in Q1 2026, an estimated $1.24M.
  • Two Sigma Advisers first reported a position in LENZ Therapeutics in Q2 2022 and held it in 9 quarters.
  • Two Sigma Advisers's LENZ Therapeutics position peaked at $1.24M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.